Dashboard: Filter Bricks
Main page content
The Advisory outlines the principles and components of low barrier care, and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.
This report for policy makers and criminal justice and behavioral health professionals provides an overview of the status of the fields of competence to stand trial, incompetence to stand trial, and competence restoration for adults and youth in the criminal justice and juvenile justice systems.
This report provides key findings from the 2022 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment among the noninstitutionalized U.S. population aged 12 or older. Estimates are presented by age group and by race/ethnicity for selected measures.
Mental Health Client-Level Data (MH-CLD) 2021: Data on Clients Receiving Mental Health Treatment Services Through State Mental Health Agencies annual report presents the total number of clients receiving mental health treatment services in 2021 by demographics, National Outcome Measures (NOMs), and the top five mental health diagnoses for children (ages 0-17) and adults (ages 18 and older) by geographic distribution.
The N-SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the key operational characteristics of substance use and mental health treatment facilities, use of pharmacotherapies, language assistance services, and suicide prevention assistance services.
This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.
An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.
Displaying 1 - 10 out of 141